AUTHOREA
Log in
Sign Up
Browse Preprints
LOG IN
SIGN UP
Derek Byers
Public Documents
1
Cycle threshold SARS-CoV-2 RT-PCR and bronchoalveolar cytokine concentrations redefin...
M Cristina Vazquez Guillamet
and 9 more
April 17, 2023
Abstract Rationale: Recent studies suggest that both hypo- and hyper-inflammatory ARDS phenotypes characterize severe COVID-19-related pneumonia. The role of lung SARS-CoV-2 viral load in contributing to these phenotypes remains unknown. Objectives: To redefine COVID-19 ARDS phenotypes when considering semi-quantitative SARS-CoV-2 RT-PCR in the bronchoalveolar lavage of intubated patients. To compare the relevance of deep respiratory samples vs plasma in linking the immune response and the semi-quantitative viral loads. Methods: Eligible subjects were adults diagnosed with COVID-19 ARDS who required mechanical ventilation and underwent bronchoscopy. We recorded the immune response in the bronchoalveolar lavage and plasma and semi-quantitative SARS-CoV-2 RT-PCR in the bronchoalveolar lavage. Hierarchical clustering on principal components was applied separately on the two compartments datasets. Baseline characteristics were compared between clusters. Measurements and Results: 20 subjects were enrolled between August 2020 and March 2021. Subjects underwent bronchoscopy on average 3.6 days after intubation. All subjects were treated with dexamethasone prior to bronchoscopy, 11 of 20 (55.6%) received remdesivir and 1 of 20 (5%) received tocilizumab. Adding viral load information to the classic two cluster model of ARDS revealed a new cluster characterized by hypo-inflammatory responses and high viral load in 23.1% of the cohort. Hyperinflammatory ARDS was noted in 15.4% of subjects. Bronchoalveolar lavage clusters were more stable compared to plasma. Conclusions: We identified a unique group of critically ill subjects with COVID-19 ARDS who exhibit hypo-inflammatory responses but high viral loads in the lower airways. Our approach adds the infection dimension to ARDS phenotypes described in COVID-19 pneumonia